Buscador de ensayos clínicos de Fight CRC
NCT ID | Title | Fase | Date Added | Ubicación | Prior IO Allowed | CRC-directed | Status | Drogas | Etiquetas |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT06455254 |
TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM | Fase
Fase 2
|
Date Added 2024-06-12 |
Ubicación
China
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas |
Etiquetas
MSS/ MMRp
|
NCT ID NCT06566755 |
TitleCadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | Fase
Fase 3
|
Date Added 2024-08-22 |
Ubicación
China
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas |
Etiquetas
MSS/ MMRp
|
NCT ID NCT05672316 |
TitleBotensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | Fase
Fase 1
|
Date Added 2023-01-05 |
Ubicación
California, United States
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Balstilimab, Botensilimab, Regorafenib |
Etiquetas
MSS/ MMRp
|
NCT ID NCT06336902 |
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | Fase
Fase 1
|
Date Added 2024-03-29 |
Ubicación
California, United States
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
Balstilimab, Botensilimab |
Etiquetas
MSS/ MMRp
|
NCT ID NCT02343991 |
TitleBlood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound | Fase
No aplicable
|
Date Added 2015-01-22 |
Ubicación
Canadá
|
Prior IO Allowed No |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
Transcranial ExABlate |
Etiquetas
MSS/ MMRp
|
NCT ID NCT01061515 |
TitleBiweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Fase
Fase 1
|
Date Added 2010-02-03 |
Ubicación
Missouri, United States
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Bevacizumab, capecitabine, Intraperitoneal Oxaliplatin, Avastin, Eloxatin, Xeloda |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03740256 |
TitleBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Fase
Fase 1
|
Date Added 2018-11-14 |
Ubicación
Texas, United States
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
CAdVEC |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03851614 |
TitleBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | Fase
Fase 2
|
Date Added 2019-02-22 |
Ubicación
Canadá
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Cediranib, durvalumab, Olaparib |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03217747 |
TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | Fase
Phase 1, Phase 2
|
Date Added 2017-07-14 |
Ubicación
Texas, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03608046 |
TitleAvelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | Fase
Fase 2
|
Date Added 2018-07-31 |
Ubicación
Bélgica
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
Avelumab, Cetuximab Injection, Irinotecan |
Etiquetas
MSS/ MMRp
|